Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Breast Cancer: Update Bulletin #2 [November 2018]

Product Code:
596201018
Publication Date:
November 2018
Format:
PDF
Price:
$1,315

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: the FDA’s approval of Pfizer's Talzenna (talazoparib), a PARP inhibitor for use in patients with germline BRCA-mutated, HER2-negative locally advanced or metastatic BC; Novartis  announcing positive results from the global Phase III SOLAR-1 trial evaluating the alpha-specific PI3K inhibitor alpelisib in combination with fulvestrant; as well as SELLAS Life Sciences Group announcing data from a Phase IIb trial of the combination of NeuVax  +/- Herceptin targeting HER2 low-expressing BC patient cohorts.

Business Questions:

• How do KOLs view the FDA approval of Talzenna (talazoparib)?
• According to KOLs, how will Talzenna be positioned?
• According to KOLs, what factors will be important in determining how successful Talzenna will be against Lynparza (olaparib)?
• What is the KOLs’ reaction to the alpelisib Phase III SOLAR-1 data?
• How does Novartis’ alpelisib compare to Roche’s taselisib?
• If approved, how do KOLs think alpelisib will be positioned?
• What do KOLs think of NeuVax Phase IIb data in HER2 low-expressing TNBC patients?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved